Abstract
The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance bioavailability through the improvement of dissolution rate and saturation solubility of drugs, by virtue of their small sizes. Nano-drugs available in the market are usually produced by top-down methods, such as wet milling and high pressure homogenization. These conventional top-down methods, however, suffer from high energy and time requirement, as well as wide and inconsistent nano-drug size distribution. Furthermore, commercially available nano-drugs are predominantly crystalline while amorphous nano-drugs are largely neglected despite their propensity to generate high saturation solubility. In this review, nonconventional methods to prepare crystalline and amorphous nano-drugs are discussed, with the bioavailability enhancing characteristics highlighted. Both top-down and bottom-up methods are covered, finally, a sustainability-based perspective comparing amorphous and crystalline nano-drugs is presented.
Keywords: Nanoparticle, nano-crystals, amorphous drug nanoparticles, bioavailability enhancement, top-down, bottom-up.
Current Pharmaceutical Design
Title:Towards Sustainability: New Approaches to Nano-Drug Preparation
Volume: 19 Issue: 35
Author(s): Wean Sin Cheow, Rong Xu and Kunn Hadinoto
Affiliation:
Keywords: Nanoparticle, nano-crystals, amorphous drug nanoparticles, bioavailability enhancement, top-down, bottom-up.
Abstract: The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance bioavailability through the improvement of dissolution rate and saturation solubility of drugs, by virtue of their small sizes. Nano-drugs available in the market are usually produced by top-down methods, such as wet milling and high pressure homogenization. These conventional top-down methods, however, suffer from high energy and time requirement, as well as wide and inconsistent nano-drug size distribution. Furthermore, commercially available nano-drugs are predominantly crystalline while amorphous nano-drugs are largely neglected despite their propensity to generate high saturation solubility. In this review, nonconventional methods to prepare crystalline and amorphous nano-drugs are discussed, with the bioavailability enhancing characteristics highlighted. Both top-down and bottom-up methods are covered, finally, a sustainability-based perspective comparing amorphous and crystalline nano-drugs is presented.
Export Options
About this article
Cite this article as:
Cheow Sin Wean, Xu Rong and Hadinoto Kunn, Towards Sustainability: New Approaches to Nano-Drug Preparation, Current Pharmaceutical Design 2013; 19 (35) . https://dx.doi.org/10.2174/1381612811319350002
DOI https://dx.doi.org/10.2174/1381612811319350002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology Assessment of miR-212 and Other Biomarkers in the Diagnosis and Treatment of HBV-infection-related Liver Diseases
Current Drug Metabolism Natural Products Mediated Regulation of Oxidative Stress and DNA Damage in Ultraviolet Exposed Skin Cells
Current Pharmaceutical Biotechnology Review: Alternative Splicing (AS) of Genes As An Approach for Generating Protein Complexity
Current Genomics Substance P Prevents Vascular Endothelial Dysfunction in Metastatic Breast Carcinoma
Protein & Peptide Letters Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Therapeutic Targeting of the Sphingolipid “Biostat” in Hematologic Malignancies (Guest Editors: Thomas P. Loughran and Hong-Gang Wang)]
Anti-Cancer Agents in Medicinal Chemistry Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Analysis of Brostallicin Effect on Different Human Gastrointestinal Cancer Cell Lines
Letters in Drug Design & Discovery Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Research Advances of Endostatin and its Short Internal Fragments
Current Protein & Peptide Science Targeting Apoptotic Pathways in Myocardial Infarction: Attenuated by Phytochemicals
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis and Biological Activity of 3-N-Substituted Estrogen Derivatives as Breast Cancer Agents
Mini-Reviews in Medicinal Chemistry Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Pharmacokinetic Study of Weekly (Days 1-5) Low-dose S-1 in Patients with Non-Small-Cell Lung Cancer
Reviews on Recent Clinical Trials Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases
Current Drug Metabolism Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Ruthenium Antimetastatic Agents
Current Topics in Medicinal Chemistry